Kocarnik JM, Compton K, Dean FE. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8(3):420–44.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Zhang SZ, Zhang L, Xie L. Cancer burden in China during 1990–2019: analysis of the global burden of disease. Biomed Res Int. 2022;2022:3918045.

PubMed  PubMed Central  Google Scholar 

Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91.

Article  PubMed  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong RM, Scotland RR, Lau RL, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19(10):1223–34.

Article  CAS  PubMed  Google Scholar 

Wang Q, Xie B, Liu S, et al. What happens to the immune microenvironment after PD-1 inhibitor therapy? Front Immunol. 2021;12: 773168.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen R, Tao Y, Xu X, et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. Discov Med. 2018;26(143):155–66.

PubMed  Google Scholar 

Qiao W, Wang Q, Hu C, et al. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. Front Immunol. 2022;13:1019772.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu K, Wu H, Zhou C, et al. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma. Int J Clin Pharm. 2023;45(3):641–9.

Article  PubMed  Google Scholar 

Joung KI, Song JH, Suh K, et al. Effect of treatment with the PD-1/PD-L1 inhibitors on key health outcomes of cancer patients. BioDrugs. 2021;35(1):61–73.

Article  CAS  PubMed  Google Scholar 

Costa L, Alexandre T, Mansinho A, et al. Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in Portugal. Front Public Health. 2023;11:1133959.

Article  PubMed  PubMed Central  Google Scholar 

Smare C, Lakhdari K, Doan J, et al. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97–108.

Article  PubMed  Google Scholar 

Rossi R, Murari A, Gaudio P, et al. Upgrading model selection criteria with goodness of fit tests for practical applications. Entropy (Basel). 2020;22(4):447.

Article  PubMed  PubMed Central  Google Scholar 

Naimark DM, Kabboul NN, Krahn MD. The half-cycle correction revisited: redemption of a kludge. Med Decis Making. 2013;33(7):961–70.

Article  PubMed  Google Scholar 

Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 2014;74(4):403–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan H, Shao ZY, Xiao YY, et al. Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. BMJ Open. 2015;5(12): e9419.

Article  Google Scholar 

Chen R, Zheng R, Zhang S, et al. Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data. J Nat Cancer Center. 2023;3(1):21–7.

Article  Google Scholar 

Zheng RS, Zhang SW, Sun KX, et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi. 2023;45(3):212–20.

CAS  PubMed  Google Scholar 

Tenen DG, Chai L, Tan JL. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf). 2021;9(1):1–13.

Article  PubMed  Google Scholar 

Harris PS, Hansen RM, Gray ME, et al. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25(13):1550–9.

Article  PubMed  PubMed Central  Google Scholar 

Chen F, Wang J, Wu Y, et al. Potential biomarkers for liver cancer diagnosis based on multi-omics strategy. Front Oncol. 2022;12: 822449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bai R, Sun J, Xu Y, et al. Incidence and mortality trends of nasopharynx cancer from 1990 to 2019 in China: an age-period-cohort analysis. BMC Public Health. 2022;22(1):1351.

Article  PubMed  PubMed Central  Google Scholar 

Carretero-Gonzalez A, Otero I, Lora D, et al. Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. Oncoimmunology. 2021;10(1):1878599.

Article  PubMed  PubMed Central  Google Scholar 

Rachev B, Wilking N, Kobelt G, et al. Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets. J Cancer Policy. 2021;28: 100279.

Article  PubMed  Google Scholar 

Chiang CL, Chan SK, Lee SF, et al. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Netw Open. 2021;4(1): e2033761.

Article  PubMed  PubMed Central  Google Scholar 

Chaudhary MA, Lubinga SJ, Smare C, et al. Cost-effectiveness of nivolumab in patients with NSCLC in the United States. Am J Manag Care. 2021;27(8):e254–60.

Article  PubMed  Google Scholar 

Aziz M, Tan LE, Tan W, et al. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. J Med Econ. 2020;23(9):952–60.

Article  PubMed  Google Scholar 

Jin Y, Li H, Zhang P, et al. The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study. Int J Cancer. 2023;152(11):2351–61.

Article  CAS  PubMed  Google Scholar